In this week’s pharma news, India’s biomedical waste problem, Singapore’s drug sector set for recovery, EFPIA warns members to prep for Brexit and more…

Biomedical waste increasing in India

India will produce 775.5 tons of medical waste – including unused medicines – a day by 2022 according to a new study.

The survey (available here) was conducted by the Associated Chambers of Commerce of India (ASSOCHAM) and market research firm Velocity to highlight the challenges involved in disposing of medical waste in the sub-continent.

The authors warned that ineffective waste management can impact on public health, citing diseases like cholera, typhoid, hepatitis and HIV as examples of epidemics that could be exacerbated.

The report also highlighted the opportunity for specialist waste management companies. According to the authors, the Indian waste management market will be worth $13.62 billion by 2025.

MHRA reminds pharma of updated trial rules

The UK MHRA has urged clinical trial sponsors to make sure they comply with recently revised safety rules.

On Wednesday the MHRA told sponsors that, from next January, trials must comply with new rules on safety information reporting for suspected unexpected serious adverse reaction (SUSARs) that were issued by the HMA in November.

Singapore’s pharma output set to soar

Pharmaceutical production in Singapore is likely to increase significantly in 2018 with new plants helping the sector regain momentum lost last year.

Usually the drug industry is the second biggest contributor to Singapore’s manufacturing output, account for 3% of the island States GDP according to the economic development board (EDB). However, drug production slumped in 2017.

But production is expected to increase in 2018 according to Ho Weng Si, director of biomedical sciences for EDB.

Weng Si told Reuters a facility being built by AbbVie, combined with increased production at Amgen and Novartis’s Singapore operations will drive growth.

Manufacturing output is also expected to benefit from the increase in drug approvals in the US last year as Singapore plays host to eight of the world’s top ten drug firms including Roche, GlaxoSmithKline, Pfizer and Sanofi.

EFPIA warns members to prepare for Brexit (again)

European drug industry group (EFPIA) has warned members to “prepare for every scenario” to ensure the supply of medicines continues after the UK leaves the EU.

In a blog post on Tuesday, EFPIA appealed to companies thinking of duplicating UK operations in a second EU member state, warning that the process can take 42 months to achieve.

“Due to the technical complexity of the analytical methodology and specific equipment required, it will be extremely challenging to transfer such knowledge from the UK to testing laboratory within the EU27 by April 2019.”

Also in the news

A Pfizer plant in McPherson, Kansas was evacuated last Monday after a bomb threat. No suspect materials were found and operations resumed the same day according to KWCH-12.

As promised, the EMA has increased what it charges drug companies for everything other than pharmacovigilance activities. See details here.

Japanese drug manufacturer Takeda has express an interest in buying Shire according to FiercePharma.